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Abstract
The antitumoral properties of endocannabinoids received a particular attention these last few years. Indeed, these
endogenous molecules have been reported to exert cytostatic, apoptotic and antiangiogenic effects in different tumor cell
lines and tumor xenografts. Therefore, we investigated the cytotoxicity of three N-acylethanolamines – N-arachidonoy-
lethanolamine (anandamide, AEA), N-palmitoylethanolamine (PEA) and N-oleoylethanolamine (OEA) - which were all able to
time- and dose-dependently reduce the viability of murine N1E-115 neuroblastoma cells. Moreover, several inhibitors of
FAAH and NAAA, whose presence was confirmed by RT-PCR in the cell line, induced cell cytotoxicity and favored the
decrease in cell viability caused by N-acylethanolamines. The most cytotoxic treatment was achieved by the co-incubation
of AEA with the selective FAAH inhibitor URB597, which drastically reduced cell viability partly by inhibiting AEA hydrolysis
and consequently increasing AEA levels. This combination of molecules synergistically decreased cell proliferation without
inducing cell apoptosis or necrosis. We found that these effects are independent of cannabinoid, TRPV1, PPARa, PPARc or
GPR55 receptors activation but seem to occur through a lipid raft-dependent mechanism. These findings further highlight
the interest of targeting the endocannabinoid system to treat cancer. More particularly, this emphasizes the great potential
benefit of designing novel anti-cancerous therapies based on the association of endocannabinoids and inhibitors of their
hydrolysis.
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Introduction
Since the identification of D
9-tetrahydrocannabinol as the main
psychoactive constituent of Cannabis sativa [1], a notable amount of
studies have been carried out in the cannabinoid field in order to
elucidate the physiological functions of the endocannabinoid
system and its potential relevance in health and diseases. To date,
two types of G protein-coupled receptors playing a role in the
endocannabinoid system have been cloned, the CB1 and CB2
cannabinoid receptors [2,3]. The two major endocannabinoids, N-
arachidonoylethanolamine (AEA, anandamide) and 2-arachido-
noylglycerol (2-AG), are endogenous bioactive lipids activating the
cannabinoid receptors [4]. However, it is now well established that
other receptors, like the vanilloid receptor 1 (TRPV1) [5], two G
protein-coupled receptors - GPR55 and GPR119 [6] - and the
peroxisome proliferator-activated receptors (PPAR’s) [7], are
involved in the pharmacological effects of cannabinoids.
Along with the endocannabinoids, other endogenous mediators
belonging to the N-acylethanolamine family and exerting canna-
bimimetic actions are known. These ‘‘endocannabinoid-like’’
compounds, including N-palmitoylethanolamine (PEA) and N-
oleoylethanolamine (OEA), do not bind the CB1 and CB2
cannabinoid receptors although they share with AEA common
metabolic pathways as well as molecular targets such as PPAR’s
[8].
Several enzymes tightly regulate endocannabinoid levels. The
best characterized is the fatty acid amide hydrolase (FAAH) [9]
which is responsible for the hydrolysis of the N-acylethanolamines
AEA, PEA and OEA. The N-acylethanolamine-hydrolyzing acid
amidase (NAAA) is another amidase catalyzing the same reaction,
although at a more acidic pH [10]. The major enzyme responsible
for the degradation of 2-AG is the monoacylglycerol lipase
(MAGL) [11].
During these last few years endocannabinoid antitumoral effects
received a particular attention, including for their ability to
decrease proliferation and viability of different cancer cell lines
both in vitro and in vivo. The mechanisms at the origin of these
effects are multifarious and implicate growth arrest, induction of
apoptosis, angiogenesis inhibition and antimetastatic effects [12].
AEA was reported to inhibit human breast cancer cell prolifer-
ation through the CB1 receptor without inducing apoptosis. 2-AG,
but not PEA, also showed analogous antiproliferative effects [13].
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on which, acting through the CB1 receptor, AEA induced massive
cell apoptosis and necrosis [14]. But cannabinoids can also exert
antitumoral effects by acting via the CB2 receptor [15], the
TRPV1 receptor [16] or through a combined activation of both
cannabinoid and vanilloid receptors [17]. In addition, though PEA
has no antiproliferative properties by itself, it was shown to
enhance AEA activity at vanilloid TRPV1 receptor [18] and to
enhance AEA-induced cytostatic effects mediated by the CB1
cannabinoid receptor [19]. An enzymatic approach has also been
described in which arachidonoyl-serotonin (AA-5-HT), a blocker
of endocannabinoid enzymatic hydrolysis, was proved to be
effective in reducing cell proliferation and tumor development
[20]. Together these studies show the implication of the
endocannabinoid system in malignancy and suggest the therapeu-
tic benefits that would offer its modulation in the treatment of
cancer.
Neuroblastoma is the most frequent extracranial solid tumor of
childhood and continues to carry a poor prognosis [21]. Lack of
efficacy of treatments made it necessary to find new therapeutic
strategies. Several cells lines, including N1E-115 (as shown by
Mundy et al. [22], Grimbly et al. [23] and Favier et al. [24]), have
been used as neuroblastoma model for studying proliferation and
cell toxicity. Furthermore, because we wanted to study the role of
the endocannabinoid system in neuroblastoma cell viability we
opted for the N1E-115 cell line that was already shown to express
CB1 cannabinoid receptors [25]. Thus, we further characterized
here the endocannabinoid system in the N1E-115 murine
neuroblastoma cell line and investigated the cytotoxicity of
endocannabinoids, their metabolism inhibition and the potential
implication of cannabinoid and non-cannabinoid receptors in cell
viability. By studying the mechanisms of activity, we point up the
possibility of enhancing the antiproliferative properties of the
endocannabinoid anandamide by inhibiting its degradation using
the selective FAAH inhibitor URB597.
Materials and Methods
1. Drugs
Anandamide, N-palmitoylethanolamine and N-oleoylethanola-
mine as well as arachidonic acid, palmitic acid and oleic acid were
all from Tocris Bioscience. The enzyme inhibitors URB597,
CAY10402 and CAY10499 were bought from Cayman Europe
and MAFP from Tocris Bioscience. CCP (N-cyclohexanecarbo-
nylpentadecylamine) was kindly synthesized by Coco N. Kapanda
(Universite ´ catholique de Louvain, Belgium). All the receptor
antagonists (AM251, capsazepine, GW6471, T0070907 and (-)-
cannabidiol) were purchased from Tocris Bioscience and the lipid
raft disruptor methyl-b-cyclodextrin was from Sigma-Aldrich. The
endocannabinoids, fatty acids, enzyme inhibitors and receptor
antagonists were prepared in DMSO at a stock concentration of
2610
22 M and diluted in media for the experiments conducted on
cells. Dilutions of methyl-b-cyclodextrin were performed in PBS
using a stock concentration of 2610
21 M. The final concentration
of DMSO was kept below 0.2%. [
3H]-anandamide (60 Ci/mmol)
and [
3H]-PEA (20 Ci/mmol) were purchased from American
Radiolabeled Chemicals (St Louis, MO, USA).
2. Cell culture
The murine neuroblastoma cell line N1E-115 was obtained
from the American Type Culture Collection and was routinely
cultured in Dulbecco’s modified Eagle medium D-MEM/NUT
mix F12 (1/1) medium supplemented with 10% fetal bovine
serum, 100 UI/ml penicillin, 100 mg/ml streptomycin and 2mM
L-glutamine. Cells were maintained at 37uC in a humidified
atmosphere of 5% CO2.
3. MTT cell viability assay
The effect on cell viability of the different treatments was
measured using MTT assay, which is based on the transformation
of 3-(4,5-dimethylthiazol-2-yl)-2,5diphenyltetrazolium bromide
(MTT) in formazan crystals by the mitochondrial succinate
dehydrogenase of viable cells. Cells were plated in 96-well plates
at a density of 2000 cells/well in D-MEM medium supplemented
with 10% serum. After 5h of incubation at 37uC in a 5% CO2
humidified atmosphere, test compounds diluted in culture medium
were added in each well for 24h, 48h or 72h. The medium was
then removed and 100 ml of MTT solution (0.3 mg/ml) were
added for a 2h incubation. The MTT solution was removed,
replaced by 100 ml DMSO to dissolve the crystalline formazan
product and the absorbance was read at 570nm (with a reading at
650nm as reference) using a microplate spectrophotometer. For
the treatments with the receptor antagonists and methyl-beta-
cyclodextrin, only the 72h time point was considered and the
antagonists were incubated 1h before the beginning of the
cytotoxic treatment.
4. Cell proliferation assay
The antiproliferative properties of tested molecules were
measured by [
3H]-thymidine incorporation assay and performed
in microwells. Cells were incubated with the drugs for 24h and
[methyl-
3H]thymidine (0.5 mCi/well) was added during the last
8h of a 24h treatment. During each cell division [
3H]-thymidine is
incorporated into the cell DNA and at the end of the incubation
the amount of radioactivity incorporated by the cells was
measured after filtration by liquid scintillation.
5. Cell death
5.1. Caspase 3 activity. Cell death by apoptosis was assessed
by measurement of caspase 3 activity monitored by cleavage of a
specific peptide substrate Asp-Glu-Val-Asp-AFC (DEVD-AFC)
according to the FluorAce apopain assay kit (Bio-Rad). After 24h
treatment with the cytotoxic agent, the cells were collected,
centrifuged and washed with PBS before lysis. After a second
centrifugation, the supernatant was incubated with the peptide
substrate and the cleavage was measured after 0, 30, 60, 90 and
120 min using a fluorescence spectrometer (375nm excitation,
530nm emission). Cells treated with 10 mM of sanguinarine for 4h
were used as positive control.
5.2. Annexin-V/Propidium iodide staining. Detection
and quantification of apoptosis was performed by the analysis of
phosphatidylserine on the outer leaflet of apoptotic cell
membranes using Annexin-V-Fluorescein. Propidium iodide was
used for the differentiation from necrotic cells. Cells were
incubated for 24h with the cytotoxic treatment before being
stained with the Roche Annexin-V-FLUOS Staining kit
(Mannheim, Germany) following the manufacturer’s instructions.
Cells treated with 5 mM of camptothecin were used as positive
control. Cells were examined using a fluorescence microscope
from Optika (Ponteranica, Italy). Pictures were taken with a
Moticam 2300 from Motic (Hong Kong, China).
6. Cell cycle analysis
Cell cycle analysis was performed on N1E-115 cells plated in 6-
well plates, initially seeded at a density of 50, 100 or 150610
3
cells/well and incubated for 24h, 48h or 72h respectively with
vehicle or both AEA and URB597 at 20 mM. When specified, cells
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addition of the tested compounds. After treatment, cells were
harvested by trypsinization, washed with PBS, pelleted and fixed
by rapid submersion in ice-cold 80% ethanol with vigorous
vortexing. After overnight fixation at 220uC, cells were washed
with PBS, pelleted, resuspended and incubated for 20min in a
saponin-based permeabilization solution containing 1% BSA,
0.2 mg/ml Ribonuclease A and 20 mg/ml propidium iodide. Data
were collected on a LSRFortessa (BD Biosciences) and analyzed
with the FlowJo software (Treestar).
7. Cell morphology
Cells were observed after various incubation times under an
inverted microscope from Optika (Ponteranica, Italy). Pictures
were taken with a Moticam 2300 from Motic (Hong Kong,
China). Light microscopic evaluation was performed using a
magnification of 400x.
8. Reverse transcriptase-polymerase chain reaction
Total RNA was extracted from the cultured cells with the
TriPure Isolation reagent (Roche). To measure mRNA expression,
reverse transcription was performed using the Reverse Transcrip-
tion System (Promega) and the generated cDNA was amplified by
PCR using the primers mentioned in the Table 1. Polymerase
chain reactions were performed according to the following
parameters: 95uC for 10min, 95uC for 3s, 60uC for 26s, and
72uC for 10s (45 cycles). After amplification, agarose gel
electrophoresis was used to detect the expression of the genes.
9. Enzymatic activity and inhibition
9.1. On cell homogenates. In order to detect the presence of
N-acylethanolamine enzymatic hydrolysis, glass tubes containing
increasing amounts of cell homogenates (165 ml, 10mM Tris-HCl,
1mM EDTA, pH 7.4) and 10 ml of DMSO were incubated for
10min at 37uC with the radiolabeled substrate (either [
3H]-
anandamide or [
3H]-N-palmitoylethanolamine (25 ml, 50000
dpm)). Reactions were stopped by rapidly placing the tubes in
ice-cold water followed by the addition of cold chloroform-
methanol (1:1 v/v, 400 ml). After centrifugation (850g, 5min, 4uC)
the radioactivity in the aqueous phase (200 ml) was counted by
liquid scintillation (UltimaGold from Perkin-Elmer). To estimate
the inhibition potential on N1E-115 cell homogenates of the
inhibitors, a set amount of homogenate was chosen (25 mgo f
protein/tube) and compounds in DMSO (10 ml), or DMSO alone
for control, were added. As control for chemical hydrolysis, dpm
values obtained for tubes containing buffer instead of proteins
were systematically subtracted.
9.2. On living cells. Cells were seeded 24h before treatment
at a concentration of 10
5 cells/well in a 24-well plate. The medium
was removed and replaced by 200 ml of fresh medium 30min
before the beginning of the experiment. Test compounds were
added to each well (150 ml) followed by the radiolabeled substrate
(50 ml, 50000 dpm) and the plate was incubated 10min at 37uCi n
a5 %C O 2 humidified atmosphere. Then, the reaction was
stopped by adding 400 ml of cold methanol on ice. After scraping
the wells, a volume of 600 ml was removed and placed in a glass
tube where 300 ml chloroform were added. The tubes were
centrifuged (850g, 10min, 4uC) and a 400 ml aliquot of the aqueous
upper phase was used to measure the radioactivity by liquid
scintillation (UltimaGold from Perkin-Elmer). Cells incubated with
vehicle (DMSO) were used as control and wells containing no cells
were used as blank.
10. N-acylethanolamine quantification by HPLC-MS
Cells (10
7 cells/flask) were seeded in 10% FBS media for 12h
prior to the incubation (2h) with the drugs, or vehicle, in 1% FBS
media. The cells were then recovered and the lipids extracted
using a CHCl3 – MeOH – H20 (10:5:2.5) mixture. Following
centrifugation, the organic layer was recovered, dried under a
stream of N2 and purified by solid-phase extraction using silica,
followed by elution with an EtOAc-Acetone (1:1) solution [26,27].
The resulting lipid fraction was analysed by HPLC-MS using a
LTQ Orbitrap mass spectrometer (ThermoFisher Scientific)
coupled to an Accela HPLC system (ThermoFisher Scientific)
[28]. Analyte separation was achieved using a C-18 Supelguard
pre-column and a Supelcosil LC-18 column (3 mM, 46150 mm)
(Sigma-Aldrich). Mobile phases A and B were composed of
MeOH-H2O-acetic acid 75:25:0.1 (v/v/v) and MeOH-acetic acid
100:0.1 (v/v), respectively. The gradient (0.5 ml/min) was
designed as follows: transition from 100% A to 100% B linearly
over 15min, followed by 10min at 100% B and subsequent re-
equilibration at 100% A. We performed MS analysis in the
positive mode with an APCI ionisation source. The capillary and
APCI vaporiser temperatures were set at 250uC and 400uC,
respectively. N-acylethanolamines were quantified by isotope
dilution using their respective deuterated standards with identical
retention. The calibration curves were generated as previously
described [26], and the data were normalised by cell number.
11. Statistical analysis
Values were expressed as mean 6 SEM. Statistical analysis was
performed by ANOVA or by unpaired Student’s t test.
Results
1. N-acylethanolamines time- and dose-dependently
decrease N1E-115 cell viability
We assessed the effect of the endocannabinoid AEA and related
bioactive lipids – PEA and OEA – on the viability of N1E-115
cells, a neuroblastoma cell line, using a MTT assay. We observed
that already after 24h of treatment, AEA, PEA and OEA (at
10 mM) are equally effective in reducing the number of
metabolically active cells, expressed as cell viability, in comparison
to vehicle, and that this effect is amplified after 48h and 72h of
incubation (Fig. 1A). We then tested increasing concentrations of
N-acylethanolamines (from 100nM up to 20 mM) to study the
dose-dependent character of the observed effect. Here, we show
that, after 72h of treatment (i.e. the time at which the effects were
most apparent), AEA, PEA and OEA decrease neuroblastoma cell
Table 1. Primer sequences used for PCR amplification.
RPL19 F: gaaggtcaaagggaatgtgttca
R: ccttgtctgccttcagcttgt
FAAH F: gagatgtatcgccagtccgt GPR55 F: atttggagcagaggcacgaacatga
R: acaggcaggcctataccctt R: agtggcgatatagtccagcttcct
NAAA F: ggttttatccctgtttcctgtttat TRPV1 F: aactcttacaacagcctgtattccaca
R: tttttgacaatacatcaccttcagct R: aagacagccttgaagtcatagttct
CB1 F: ctgatgttctggatcggagtc PPARa F: caacggcgtcgaagacaaa
R: tctgaggtgtgaatgatgatgc R: tgacggtctccacggacat
CB2 F: tgacaaatgacacccagtcttct PPARc F: ctgctcaagtatggtgtccatga
R: actgctcaggatcatgtactcctt R: tgagatgaggactccatctttattca
doi:10.1371/journal.pone.0026823.t001
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cytotoxicity was not due to the N-acylethanolamine fatty acid
metabolites – i.e. arachidonic acid, palmitic acid and oleic acid for
AEA, PEA and OEA respectively – we tested these fatty acids at
0.1 mM, 1 mM and 10 mM. Although a little effect was observed
for palmitic acid and oleic acid (see Fig. S1) this was not sufficient
to account for the N-acylethanolamine-mediated reduction of cell
viability.
2. N-acylethanolamine enzymatic degradation
Since the aim of this work was to study the effect of N-
acylethanolamines on N1E-115 cell viability, we found primor-
dial to determine the rate of hydrolysis of these bioactive lipids
by the cells. Thus, using [
3H]-AEA and [
3H]-PEA, we found
that N1E-115 cell homogenates significantly hydrolyze N-
acylethanolamines (Fig. 2A and 2B). Accordingly, we detected
in N1E-115 cells the mRNA coding for the two major N-
acylethanolamine degrading enzymes, the fatty acid amide
hydrolase (FAAH) and the N-acylethanolamine-hydrolyzing acid
amidase (NAAA) (Fig. 2C). Consistent with the results obtained
with homogenates (at pH 7.4), we were also able to detect the
hydrolysis of [
3H]-AEA and [
3H]-PEA when using N1E-115
cells in culture (Table 2). Note that the hydrolysis of OEA could
not be directly tested as no radiolabeled analogue is commer-
cially available.
As enzymatic activities for the hydrolysis of N-acylethanola-
mines were detected, we sought to determine whether it would be
possible to block this hydrolysis in order to increase the effects on
cell viability observed with AEA, PEA and OEA.
3. Inhibition of N-acylethanolamine degradation
We tested at 1 mM and 10 mM several drugs able to decrease N-
acylethanolamine hydrolysis either by inhibiting selectively FAAH
(URB597 and CAY10402) or NAAA (CCP), or by concomitant
inhibition of FAAH and MAGL (MAFP and CAY10499) (see Fig.
S2). The inhibition assays were performed either on total cell
homogenates or on cells in culture (Table 2) to confirm that the
inhibitors reach their targets in culture conditions.
As expected, URB597, CAY10402, MAFP and CAY10499 all
inhibit AEA hydrolysis in homogenates and cultured cells. Note
that the inhibition is slightly less pronounced in the later case,
especially for CAY10402 which at 1 mM inhibited 4367.5% of
AEA hydrolysis in intact cells compared to 10060.7% on cell
homogenates. The NAAA inhibitor, CCP, had almost no effect on
AEA hydrolysis both in homogenates and in intact cells.
The proposed metabolic pathways for PEA and AEA are
relatively similar. Accordingly, the inhibitors similarly affected
PEA and AEA hydrolysis, although PEA hydrolysis was less
sensitive to inhibition. Surprisingly we did not observe an
inhibition of PEA hydrolysis when using CCP in homogenates
or only a slight decrease in intact cells (2264.9% inhibition at
10 mM). This could be explained by the fact that FAAH can also
hydrolyze PEA and thus that FAAH could compensate for the
decrease in NAAA activity upon inhibition by CCP [29]. Another
possible explanation is that the assay was performed on
homogenates at physiological pH while it is known that NAAA
activity is the highest at acidic pH [10].
Figure 1. N-acylethanolamines induce N1E-115 neuroblastoma
cell cytotoxicity. N-acylethanolamines AEA, PEA and OEA time- (A)
and dose-dependently (B) decrease N1E-115 cell viability. Cells were
seeded 5h before treatment (2000 cells/well in microwells) and
incubated with increasing concentrations of N-acylethanolamines. After
24h, 48h or 72h of treatment, cytotoxicity was assessed by a MTT test.
Data are expressed as percentage of the vehicle control and are the
mean of three experiments performed in quintuplicate. Significantly
different (**P,0.01) from vehicle incubation.
doi:10.1371/journal.pone.0026823.g001
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N1E-115 cell viability
With these results in hand we moved on to evaluate the effects
of the inhibitors alone, as well as these compounds in combination
with the N-acylethanolamines, on cell viability. Thus we evaluated
the cytotoxicity of these five inhibitors at 10 mM after 72 hours of
incubation. While the reversible FAAH inhibitor CAY10402 did
not provoke any cytotoxicity, the irreversible FAAH inhibitors
URB597, MAFP and CAY10499 induced a significant decrease in
cell viability (Fig. 3). Interestingly, these compounds were also the
most potent at inhibiting AEA and PEA hydrolysis in intact N1E-
115 cells (Table 2). The NAAA inhibitor CCP also significantly
reduced cell viability, even though we were not able to detect its
effects on N-acylethanolamine hydrolysis (Fig. 3).
Next we co-incubated AEA, PEA and OEA (10 mM) with
URB597, CAY10402, MAFP and CAY10499 (10 mM) to
determine whether there would be an enhancement of the
individual effects on cytotoxicity. Here we did not use CCP
anymore because it was poor at inhibiting N-acylethanolamine
hydrolysis in our cellular model. The reduction of cell viability
produced by the N-acylethanolamines AEA, PEA and OEA was
enhanced by the FAAH inhibitor URB597, with a much more
pronounced response observed for the co-incubation of URB597
with AEA (Fig. 4A). A significant decrease in cell viability was also
observed with the other selective FAAH inhibitor CAY10402
when incubated with AEA, PEA or OEA (Fig. 4A, 4B and 4C).
Thus, for the next experiments we focused on the AEA-URB597
combination which, we found, produces the highest cytotoxicity
(Fig. 4A).
5. AEA and URB597 co-incubation produces a decrease in
N1E-115 cell proliferation without inducing cell apoptosis
or necrosis
With the aim to characterize the mechanism involved in the
cytotoxicity of the AEA-URB597 combination, we first evaluated
the influence of these molecules on N1E-115 cell proliferation and
could observe a dose-dependent inhibition of [
3H]-thymidine
incorporation for the endocannabinoid and its metabolism
inhibitor (EC50=45mM and 31 mM for AEA and URB597
respectively) after 24h of treatment (Fig. 5A). Co-incubation of
AEA at 10 mM and URB597 at 10 mM reduced cell proliferation
by 50% compared to the vehicle control. Interestingly, URB597
alone decreased cell proliferation only by 21% at 10 mM, while
AEA at the same concentration had practically no effect on cell
growth. Similar results were obtained when AEA and URB597
were used at 20 mM and 1 mM alone or in a combination. Taken
together these results suggest a synergistic action of the two
compounds on N1E-115 cell proliferation.
By examining the cells after 24h, 48h or 72h of incubation with
the tested compounds, almost no apoptotic cells were observed
when looking at the morphology and when compared to the well-
known apoptosis inducer sanguinarine (10 mM) (see Fig. S3).
No caspase 3 activity could be detected in our cells even after
the 24 first hours of treatment with 20 mM of AEA and URB597
alone or in combination, whereas sanguinarine caused an increase
in caspase 3 activity after 4 hours (Fig. 5B). Additionally, when
looking at the percentage of apoptotic cells and necrotic cells,
represented by annexin-V positive cells (A+/PI-) and double
stained cells (A+/PI+) respectively, we could not observe any
difference between cells treated with 20 mM of AEA and/or
URB597 as compared to vehicle after 24h of incubation (Fig. 5C).
We used camptothecin (5 mM, 6h incubation) as positive control
for apoptosis induction and found a significant increase in the
Figure 2. N1E-115 cells efficiently hydrolyze N-acylethanola-
mines. Enzymatic activities for AEA (A) and PEA (B) hydrolysis were
measured in N1E-115 cell homogenates using [
3H]-AEA and [
3H]-PEA,
respectively. Data are the mean of three experiments performed in
duplicate. N1E-115 cells express N-acylethanolamines degrading
enzymes FAAH and NAAA (C). Detection of mRNA was performed by
RT-PCR using respectively mouse liver and lung as control and RPL19 as
house keeping gene (blot representative of three).
doi:10.1371/journal.pone.0026823.g002
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(A+/PI+). Note that similar results were obtained when incubating
the cells for 72h instead of 24h (data not shown).
6. Alteration of N1E-115 cell cycle progression induced
by AEA and URB597
Since treatment of N1E-115 cells did not induce cell death, we
hypothesized that the antiproliferative effect observed with AEA
and URB597 might be the consequence of an arrest or slow-down
in cell cycle progression. In agreement with the results obtained
with [
3H]-thymidine incorporation, we observed a significant
accumulation of cells in G1-phase (5360.5% for AEA-URB597;
2362.4% for vehicle) (Fig. 6A), with a concomitant decrease in S-
phase cells (3460.6% for AEA-URB597; 6561.1% for vehicle)
(Fig. 6B), when comparing treated and untreated cells after 24h of
incubation. However, when looking at cell cycle distribution after
48h and 72h of treatment, no additional accumulation of cells in
G1-phase was noticed. The percentage of treated cells in G2-phase
only decreased after 48h of treatment (Fig. 6C). Furthermore, we
observed only small variations in cell cycle distribution of treated
cells between the three times of measure, while untreated cells
continued to progress through the cell cycle.
In addition, cells were pretreated with nocodazole in order to
provoke mitotic arrest and accumulation of cells in G2-phase. In
this case, when looking at cell cycle distribution following 24h of
treatment with AEA-URB597 or vehicle, we observed no
significant difference in the proportion of cells in G1-phase
(Fig. 6D) and a smaller percentage in S-phase cells (Fig. 6E). A
higher percentage of cells in G2-phase was noticed (Fig. 6F) though
a overall decrease of their proportion in this phase throughout the
treatment. We could then conclude that N1E-115 cells were not
blocked in G2-phase.
Taken together, these results indicate a global slow-down of the
cell cycle progression that appears to extend to all phases of the cell
cycle. Nevertheless, we suggest a probable reduced transition
through the G1/S checkpoint, leading to accumulation of cells in
G1-phase, as displayed by the cell distribution observed after the
first 24h of incubation.
7. Investigation of the potential molecular mechanism
mediating N-acylethanolamine cytotoxicity on N1E-115
cells
As URB597 and AEA both induce a decrease in cell
proliferation, we first asked whether URB597 could act by
increasing AEA levels. The aim of this experiment was to
determine if URB597 could actually inhibit FAAH and modify
AEA levels in our conditions. Thus we measured by an isotope-
dilution HPLC-MS method the levels of AEA (as well as PEA and
OEA) in N1E-115 cells. We found that incubating the cells with
URB597 (1 mM, 2h) results in increased AEA levels up to 193% of
the control (Fig. 7A). Note that, PEA and OEA levels were also
enhanced (Fig. 7B and 7C).
To identify the molecular targets that could mediate the N-
acylethanolamines / inhibitors cytotoxic effects, we looked by RT-
PCR for the presence in N1E-115 of the reported N-acylethano-
Table 2. Inhibition of N-acylethanolamine hydrolysis by N1E-115.
Hydrolysis inhibition (%± SEM)
AEA hydrolysis PEA hydrolysis
Cell homogenates Intact cells Cell homogenates Intact cells
URB597 10 mM 10060.2 8562.9 9661.9 7366.5
1 mM 9960.3 8662.0 8763.4 7464.3
CAY10402 10 mM 10060.5 6266.2 8962.5 6667.0
1 mM 10060.7 4367.5 8561.4 5867.6
MAFP 10 mM 10060.3 8662.9 8961.8 6366.0
1 mM 10060.2 9263.1 8461.9 6265.3
CAY10499 10 mM 10060.5 9362.5 8861.7 6863.5
1 mM 9060.6 8161.8 8062.2 5565.1
CCP 10 mM 362.5 964.0 763.1 2264.9
1 mM 662.0 363.4 563.7 965.6
FAAH inhibitors (URB597, CAY10402), NAAA inhibitors (CCP) and dual inhibitors of FAAH and MAGL (MAFP, CAY10499) were tested at concentrations of 1 and1 0mMo n
cell homogenates (25 mg protein, pH 7.4) and on intact cells (10
5 cells/well, seeded 24h before) in culture medium. Data are the mean of three experiments and are
expressed as percentage of the control containing vehicle instead of the inhibitors.
doi:10.1371/journal.pone.0026823.t002
Figure 3. N-acylethanolamine hydrolysis inhibitors decrease
N1E-115 cell viability. Cells were seeded 5h before treatment (2000
cells/well in microwells) and incubated with inhibitors at a concentra-
tion of 10 mM. After 72h of treatment, cytotoxicity was assessed by a
MTT test. Data are the mean of three experiments performed in
quintuplicate and are expressed as percentage of the vehicle control.
Significantly different (**P,0.01) from vehicle incubation.
doi:10.1371/journal.pone.0026823.g003
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CB1, but not CB2 cannabinoid receptor (Fig. 8A) [25]. Other
receptors implicated in N-acylethanolamine actions were also
detected: the G protein-coupled receptor GPR55, the vanilloid
cation channel TRPV1 and the nuclear receptors PPARa and
PPARc (Fig. 8A).
Based on the above data, we used selective antagonists in order
to study the involvement of these receptors in AEA and/or
URB597 cytotoxicity. Thus we used AM251, capsazepine,
GW6471, T0070107 and cannabidiol, that are antagonists of the
CB1, TRPV1, PPARa, PPARc and GPR55 receptors, respective-
ly. Cytotoxicity of AEA (10 mM), URB597 (10 mM) or both
molecules co-incubation was not significantly affected by CB1
receptor antagonist (0.1 and 1 mM), TRPV1 receptor antagonist
(10 and 100 nM), PPAR’s receptor antagonists (0.1 and 1 mM) and
GPR55 receptor antagonist (0.1 and 1 mM) (Fig. 8B, 8C and 8D).
Similar observations were made when using smaller AEA and
URB597 concentrations (data not shown). Note that the
antagonist concentrations were chosen based on the literature
and that the drugs were assayed alone to rule out the possibility
that they could affect N1E-115 cell viability by themselves (see Fig.
S4).
As we confirmed that AEA- and URB597-induced antiprolif-
erative effects are not mediated by the classical molecular targets
of this endocannabinoid, we next studied the possible implication
of receptor-independent effects involving changes in cell mem-
brane. We thus tested methyl-b-cyclodextrin (MCD, 1mM), a lipid
raft disruptor frequently used to study the implication of these
membrane microdomains in the cytotoxicity of numerous
molecules such as cannabinoids. We saw here that MCD totally
reversed the cytotoxicity mediated by AEA (10 mM), URB597
(10 mM) and both molecules co-incubation without modifying cell
viability by itself (Fig. 8E).
Discussion
The role of endocannabinoids in cancerogenesis has largely
been explored in previous studies where they were mainly
described as protective agents against tumor development. Indeed
it has been shown using synthetic cannabinoid ligands that
Figure 4. URB597 and CAY10402 potentiate N-acylethanolamine cytotoxicity. The FAAH inhibitors URB597 and CAY10402 potentiate AEA
(A), PEA (B) and OEA (C) cytotoxicity. N1E-115 cells were seeded 5h before treatment (2000 cells/well in microwells) and incubated with the N-
acylethanolamines (10 mM) with or without URB597, CAY10402, MAFP, or CAY10499 (at 10 mM). After 72h of treatment, cytotoxicity was assessed by a
MTT test. Data are the mean of three experiments (performed in quintuplicate) and are expressed as percentage of the vehicle control. Statistical
analysis were realized between each endocannabinoid alone compared to the endocannabinoid in presence of the inhibitor. Significantly different
(*P,0.05; **P,0.01) from N-acylethanolamine incubation.
doi:10.1371/journal.pone.0026823.g004
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PLoS ONE | www.plosone.org 7 October 2011 | Volume 6 | Issue 10 | e26823Figure 5. AEA and URB597 decrease cell proliferation without inducing apoptosis. N1E-115 cell proliferation was assed by [
3H]-thymidine
incorporation (A). The cells were seeded 5h before treatment (2000 cells/well in microwells) and incubated with increasing concentrations of AEA
and/or URB597. After 16h of treatment, [methyl-
3H]thymidine (0.5 mCi/well) was added during the last 8h of a 24h treatment. Data are the mean of
three experiments (in quintuplicate) and are expressed as percentage of radiolabeled thymidine incorporation by vehicle control treated cells.
Significantly different (*P,0.05; **P,0.01) from vehicle incubation. Caspase-3 activity (B) was measured in N1E-115 cells (4610
5 cells) after treatment
with AEA, URB597 or a AEA-URB597 combination (20 mM, 24h). As a negative control, cells were treated with an equivalent volume of vehicle and a
positive control was constituted by a 4h treatment with sanguinarine (10 mM). Data are expressed in pmoles of AFC (7-amino-4-
trifluoromethylcoumarin) produced per min (U) (n=3). Significantly different (**P,0.01) from vehicle incubation. Apoptosis was assessed by
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cancer cell growth and tumor development. However, beside the
strategy consisting of activating cannabinoid receptors using the
exogenous administration of agonists, it is possible to activate those
receptors by increasing the levels of endocannabinoids. Thus the
aim of this study was to investigate the cytotoxicity of N-
Annexin-V (A) staining and Propidium Iodide (PI) was used for the differentiation from necrosis (C). N1E-115 cells were treated with 20 mM of AEA
and/or URB597 for 24h and the number of Annexin-V positive cells (A+/PI-) and of double stained cells (A+/PI+) was expressed as a percentage of
total cells. Camptothecin (5 mM) was used as positive control. Data are the average of five random fields from experiments performed in triplicate.
Significantly different (**P,0.01) from vehicle incubation.
doi:10.1371/journal.pone.0026823.g005
Figure 6. Alteration of N1E-115 cell cycle progression induced by AEA and URB597. Cells were seeded 5h before treatment (50, 100 or
150610
3 cells/well) and incubated for 24h, 48h or 72h respectively with vehicle (&) or AEA and URB597 (m)a t2 0mM. Flow cytometric results show
the percentages of cell population in G1 (A), S (B) and G2 (C). Part of cells were pretreated with nocodazole (30ng/ml, 14h) prior to the addition of AEA
and URB597 and percentages of cell population in G1 (D), S (E) and G2 (F) was measured (n=2). Significantly different (*P,0.05; **P,0.01;
***P,0.001) from vehicle incubation.
doi:10.1371/journal.pone.0026823.g006
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their antiproliferative effects by inhibiting their hydrolysis.
As we expected, treatment of the neuroblastoma cell line N1E-
115 with the endocannabinoid N-acylethanolamine AEA decreased
cell viability. Indeed, the cytotoxicity of endocannabinoids on
tumoral cells has been frequently reported. AEA has been shown to
inhibit cholangiocarcinoma growth [30], to exert cytotoxic and
antiproliferative effects on colorectal carcinoma cells [31,32] and to
cause apoptosis of osteocarcinoma cells [33] and glioma cells [16].
In our model, PEA and OEA also dose-dependently decreased
cell viability. OEA cytotoxicity has been described as being the
result of ceramide accumulation leading to cell apoptosis [34].
However, PEA was known to enhance the antiproliferative effect
of endocannabinoids but not to exert cytotoxic effect by itself even
at concentrations up to 10 mM [19,35]. Here we clearly observed a
dose-dependent cytotoxicity for PEA at concentrations below
10 mM. In order to evaluate if N-acylethanolamine degradation is
indirectly responsible for cytotoxicity [31] we tested their acyl
chain metabolites, arachidonic acid, palmitic acid and oleic acid
and found that they were not responsible for the effect observed
with the N-acylethanolamines.
As N-acylethanolamines are actually responsible for the
cytotoxicity, we sought to investigate whether increasing their
levels would affect the viability of our cells. Thus, we first looked
for the presence of enzymatic activities degrading AEA and PEA
in the neuroblastoma cell line. We detected an enzymatic
hydrolysis for AEA, both in homogenates and in intact cells, that
can be mostly attributed to the expression of FAAH. Similarly an
enzymatic hydrolysis of PEA was also detected which can be
explained, as for AEA hydrolysis, by the expression by the cells of
FAAH but also NAAA mRNA. We then assayed several N-
acylethanolamine hydrolysis inhibitors to see whether we could
block their hydrolysis in cell homogenates and in intact cells. As
expected all the inhibitors were less potent when tested on intact
cells compared to cell homogenates. Nevertheless they were still
able to significantly inhibit N-acylethanolamine degradation, with
the exception of the NAAA inhibitor CCP. It is worth also
mentioning that the reversible FAAH inhibitor CAY10402 was
markedly less potent in inhibiting AEA hydrolysis compared to the
irreversible inhibitors (URB597, CAY10499, and MAFP). This
can be related to the larger effect of URB597 in reducing cell
viability compared to CAY10402 (Table 2 and Fig. 3). One
explanation for this lack of cytotoxicity might reside in the
reversible character of FAAH inhibition by CAY10402, compared
to the irreversible inhibition mediated by the other inhibitors
tested, or an insufficient enzyme inhibition. The dual FAAH/
MAGL inhibitors (MAFP and CAY10499) caused a significant
decrease in cell viability that could be related to their ability to
almost fully inhibit AEA hydrolysis at the tested concentrations.
However, we have to keep in mind that these unselective inhibitors
can also influence 2-AG hydrolysis via their action on the MAGL.
Even though cytotoxic effects of 2-AG have also been found in
many cell types, like prostate cancer [36,37] or glioma [38], its
antitumor properties are still controversial. Indeed, recent studies
showed opposed events on cholangiocarcinoma growth where 2-
AG acted like a growth-promoting agent, while AEA had
antiproliferative effects [39,40]. The conflicting actions of 2-AG
have been evidenced when looking at the invasive properties of
prostate carcinoma cells as well. Endogenous 2-AG was anti-
invasive whereas cells treated with high doses of 2-AG saw their
invasiveness enhanced [36]. However, we allow for the possibility
that URB597 could also exert cytotoxic effects independent of its
action on AEA hydrolysis.
To identify N-acylethanolamine - N-acylethanolamine hydrolysis
inhibitorcombinationsthatwouldincreasecytotoxicityonN1E-115
cells, we tested AEA, PEA and OEA with inhibitors able to modify
their hydrolysis in the same conditions. The incubation of cells with
10 mM of AEA and URB597 was found to be the most cytotoxic
and reduced cell viability down to 30%. The FAAH inhibitor
CAY10402 was slightly less efficient in improving AEA cytotoxicity
maybe because of its reversible character compared to URB597.
According to this, and to the fact that CAY10402 did not
significantly decrease cell viability by itself, the decrease in cell
viability caused by the combination AEA-URB597 might be in part
attributed to the enhancement of AEA cytotoxicity. The same
explanations could be held for the enhancement of PEA and OEA
Figure 7. URB597 increases N1E-115 N-acylethanolamine
levels. URB597 increases intracellular levels of AEA (A), PEA (B) and
OEA (C) as measured by HPLC-MS. N1E-115 cells were seeded (12.5610
6
cells) and incubated for two hours with URB597 (1 mM). Data are the
mean of three experiments performed in quadruplicate and are
expressed as percentage of the vehicle control. Significantly different
(***P,0.001) from vehicle incubation.
doi:10.1371/journal.pone.0026823.g007
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profile as AEA even though the effects were less marked, maybe
because AEA is a better substrate for FAAH while NAAA is known
to more selectively hydrolyze PEA [41]. Interestingly, the two dual
inhibitorsMAFP and CAY10499 didnot affect N-acylethanolamine
cytotoxicity even though they potently inhibited their hydrolysis in
cultured cells and had cytotoxic effects by themselves. However, as
described previously, these molecules are unselective and might
interact with MAGL or other enzymes regulating lipid metabolism
in the cell and therefore lead to less predictable effects.
We next sought to better characterize the mechanism of action
of the combination AEA-URB597 as it was the most active in
reducing N1E-115 cell viability. We showed that AEA and
URB597 decreased [
3H]-thymidine incorporation without induc-
ing caspase-3 activation or increasing the percentage of apoptotic
or necrotic cells. Treatment with AEA and URB597 slowed N1E-
115 cell cycle progression and reduced transition through the G1/
S checkpoint, causing accumulation of cells in G1-phase. Thus, we
believe that the decrease in cell viability detected using the MTT
assay consists in decreased cell proliferation rather than in cell
death by apopotosis or necrosis. The antiproliferative properties of
AEA have previously been shown at similar concentrations in rat
glioma [17] but also in human colon cancer cells where AEA
decreases polyamine levels [42], in human cholangiocarcinoma via
Figure 8. Investigation of the potential N-acylethanolamine molecular targets in N1E-115 cells. N1E-115 cells express cannabinoid
receptor CB1 but not CB2, G-protein coupled receptor GPR55, vanilloid receptor TRPV1 and nuclear receptors PPARa and PPARc (A). Detection of
mRNA was performed by RT-PCR using mouse brain, spleen and liver as control. The blots are representative of three. Cytotoxicity of AEA (10 mM) (B),
URB597 (10 mM) (C) and AEA + URB597 (D) was not significantly affected by CB1 receptor antagonist (AM251 - 0.1 and 1 mM), TRPV1 receptor
antagonist (capsazepine - 10 and 100 nM), PPAR’s receptor antagonists (GW6471 and T0070907 - 0.1 and 1 mM) and GPR55 receptor antagonist
(cannabidiol, CBD - 0.1 and 1 mM). N1E-115 cells were seeded 5h before treatment (2000 cells/well in microwells) and incubated with AEA alone
(10 mM), URB597 alone (10 mM) and combinations of these two molecules. Antagonists were added 1h prior to the addition of AEA and/or URB597. A
MTT test was used to evaluate the percentage of viable cells remaining after 72h. Data are the mean of three experiments performed in triplicate and
are expressed as percentage of the vehicle control. Disruption of lipid rafts inhibits AEA and URB597 mediated effects on N1E-115 cell viability (E).
Cells were preincubated with methyl-b-cyclodextrin (MCD, 1mM) for 1h prior to the addition of 20 mM of AEA and/or URB597. Cell viability after 72h
was assessed with a MTT test. Methyl-b-cyclodextrin had no effect by itself. Data are the mean of three experiments performed in triplicate and are
expressed as percentage of the vehicle control. Significantly different (**P,0.01) from vehicle incubation. Significantly different (###P,0.001) from
incubation without MCD.
doi:10.1371/journal.pone.0026823.g008
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in human breast cancer and rat thyroid epithelial cancer cell lines
via a modulation of expression and activity of key S phase
regulatory proteins [13,43,44]. However, AEA has also been
described as being an apoptosis inducer in many cell types like
colorectal cancer, gastric cancer, osteosarcoma, glioma or prostate
cancer cell lines [16,33,45–47]. Of note, depending on the method
used, we observed slight differences in the effects of the tested
molecules. Indeed, AEA was more effective in the MTT assay
compared to the [
3H]-thymidine assay. This could be attributed to
the fact that cannabinoids, and more particularly AEA, were
reported to affect mitochondrial function [48–51]. Since the MTT
test consists in measuring mitochondrial succinate dehydrogenase
activity of viable cells, the above described observations could
explain the small variation obtained when comparing with [
3H]-
thymidine uptake at the same time and at the same concentration.
We show here that in our cell model, URB597 increases N-
acylethanolamine intracellular concentrations, supporting the idea
that its own cytotoxicity, and the ability of this FAAH inhibitor to
enhance AEA antiproliferative effects, might be due to an influence
on AEA levels but also of the other N-acylethanolamine levels.
Indeed, these lipid mediators decrease cell viability by themselves
but have also been described as being ‘‘entourage agents’’
potentiating AEA effects [35]. Furthermore, the implication of
FAAH in cytotoxicity has been demonstrated in the liver where
URB597could enhance AEA-induced cell death [52]. Note that the
discrepancy between the doses needed to obtain a reduction in cell
proliferation when exogenously adding AEA (or OEA and PEA)
and those obtained following FAAH inhibition by URB597 are not
surprising. Indeed, it is well known that exogenously added
endocannabinoids tend to stick to the culture plates thus reducing
their bioavailability and therefore requiring higher concentrations
than expected based on their affinity for their molecular targets. On
the contrary, locally produced endocannabinoids (i.e. through
inhibition of their catabolic enzymes) are readily available to
interact with their target, thus explaining the lower concentrations
needed to obtain a similar effect.
In order to elucidate the mechanism by which AEA and
URB597 decrease cell viability, we used antagonists of the
receptors for which mRNA was detected (CB1, TRPV1,
GPR55, PPARa and PPARc) to see whether we could block
their antiproliferative effects. The lack of efficacy of these
antagonists suggests that receptor-independent mechanisms are
involved in the reduction of cell viability observed here. Indeed,
we showed that the integrity of the lipid raft structure is required to
mediate AEA and URB597 antiproliferative effects. Lipid rafts are
specific membrane microdomains enriched in cholesterol playing a
key role in membrane fluidity and protein trafficking [53]. They
allow signaling molecules to concentrate and interact in order to
facilitate signal transduction. Focusing on cancer biology, there is
now growing evidence that lipid rafts are implicated in cell death,
proliferation and migration [54,55]. The role of lipid rafts in AEA
cytotoxicity was previously described in HepG2 liver cancer cells
and cholangiocarcinoma but, in both cases, these cytotoxic effects
were also dependent of cannabinoid CB1 or CB2 receptors which
could be controlled by these specific membrane microdomains
[56,57]. Similarly to what we observed here, DeMorrow et al.
described lipid raft-mediated AEA cytotoxicity that was not
prevented by cannabinoid receptor antagonists. Of note, AEA was
described to induce cell death via an accumulation of ceramide
and the recruitment of the Fas death receptor [39], although we
observed here no induction of cell death but an inhibition of cell
proliferation. Finally, we demonstrated here that URB597 exerts
similar antiproliferative effects as AEA without inducing apoptosis
or necrosis. Since we showed that this FAAH inhibitor increases
the concentration of AEA and other N-acylethanolamines known
to enhance AEA effects, we suggest that URB597 effects could be
partly attributed to its ability to modulate AEA levels and then
potentiate AEA effects on cell proliferation.
To conclude, we confirm here in a N1E-115 neuroblastoma
model the antiproliferative effects of AEA. Additionally, we put
into light the ability of URB597 to reduce cell proliferation, but
not to induce apoptosis or necrosis, partly via enhancing N-
acylethanolamine levels. This effect is independent of the known
molecular N-acylethanolamine targets - cannabinoid, TRPV1,
PPARa/c or GPR55 receptors – activation, but relies on a lipid
raft-mediated mechanism. Hence, the present report opens the
way to potential N-acylethanolamine-based treatments aiming at
reducing cancer cell proliferation through inhibition of their
degradation.
Supporting Information
Figure S1 Arachidonic acid (AA), palmitic acid (PA) and
oleic acid (OA) do not or only slightly decrease N1E-115
viability. The cells were incubated with 0.1 mM, 1 mM, and
10 mM of AA, PA and OA. After 72h of treatment, cytotoxicity
was assessed by a MTT test. Data are expressed as percentage of
the vehicle control and are the mean of three experiments
performed in quintuplicate. Significantly different (**P,0.01) from
vehicle incubation.
(TIF)
Figure S2 Structures of the endocannabinoid metabo-
lism inhibitors used in this study
(TIF)
Figure S3 Morphology of N1E-115 cells after treatment
with AEA and URB597. N1E-115 cells do not die by apoptosis
but still proliferate after treatment with AEA and URB597.
Pictures of N1E-115 cells were taken after 24h, 48h and 72h of
treatment with 20 mM of AEA, URB597 or a combination of both
molecules, or with the vehicle control. Treatment of 4h with
10 mM of the inducing apoptosis compound sanguinarine was
used to compare morphology.
(TIF)
Figure S4 Cytotoxicity of receptor antagonists. Cytotox-
icity of CB1 receptor antagonist (AM251), TRPV1 receptor
antagonist (capsazepine), PPARa and PPARc receptor antagonists
(GW6471 and T0070907 respectively) and GPR55 receptor
antagonist (cannabidiol, CBD). N1E-115 cells were seeded 5h
before treatment (2000 cells/well in microwells) and incubated
with the antagonists. A MTT test was used to evaluate the
percentage of viable cells remaining after 72h. Data are expressed
as percentage of the vehicle control and are the mean of three
experiments performed in quintuplicate.
(TIF)
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